Back

Impact of BRCA mutation status on tumor infiltrating lymphocytes (TILs), response to treatment, and prognosis in breast cancer patients treated with neoadjuvant chemotherapy.

2020-09-28 oncology Title + abstract only
View on medRxiv
Show abstract

IntroductionFive to 10% of breast cancers (BCs) occur in a genetic predisposition context (mainly BRCA pathogenic variant). Nevertheless, little is known about immune tumor infiltration, response to neoadjuvant chemotherapy (NAC), pathologic complete response (pCR) and adverse events according to BRCA status. Material and methodsOut of 1199 invasive BC patients treated with NAC between 2002 and 2012, we identified 267 patients tested for a germline BRCA pathogenic variant. We evaluated pre-NAC ...

Predicted journal destinations